

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD



Sunday, May 19, 2024

6:15 PM ET Dinner

6:30-8:00 PM ET Presentation

The Capital Hilton Hotel

Congressional/Senate



This program is not affiliated with Digestive Disease Week®

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Activity Description

Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize IL-23 by binding the Fab fragment to the P19 domain, the differences in Fc fragment structure may impact potency and clinical efficacy. Fc structure differences have been shown to impact binding of different agents to CD64-positive myelocytes, a main source of IL-23 in active IBD.

In this CME Outfitters symposium, expert faculty will review the role of the IL-23/Th-17 pathway in the pathogenesis of IBD and utilize animated 3-D models to illustrate differences in agents in the anti-IL-23 class that may have potential therapeutic implications. Learners will be guided through an evaluation of the potential clinical implications of CD64 receptor binding by anti-IL-23 mABs in IBD treatment, as well as the clinical evidence supporting the benefits of these IBD treatment features.

Target Audience

Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), and nurses

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Evaluate the role of various pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
- Identify the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
- Assess the potential clinical implications of the ability of anti-IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23-producing cells

Faculty

Miguel Regueiro, MD (Moderator)

Chief, Digestive Disease Institute

Professor in the Department of Medicine

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Cleveland, OH

Jessica R. Allegretti, MD, MPH, FACP, AGAF

Medical Director, Infusion Services

Director, Crohn's and Colitis Center

Director of Clinical Research

Director, Fecal Microbiota Transplant Program

Division of Gastroenterology, Hepatology and Endoscopy

Brigham and Women's Hospital

Associate Professor of Medicine, Harvard Medical School

Boston, MA

Angelina E. Collins, MSN, ANP-BC

Board Certified Nurse Practitioner

Inflammatory Bowel Disease Center

UC San Diego Health

La Jolla, CA

Edward V. Loftus, Jr., MD

Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD

Division of Gastroenterology and Hepatology

Mayo Clinic College of Medicine and Science

Co-Director, Advanced Inflammatory Bowel Disease Fellowship

Mayo Graduate School of Medicine

Rochester, MN

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Accreditation



JOINTLY ACCREDITED PROVIDER*
INTERPROFESSIONAL CONTINUING EDUCATION

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE CREDIT™

ICPE

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Nurses (ANCC)

This activity is designated for 1.5 contact hours. Nurse practitioners can apply for *AMA PRA Category 1 Credit(s)*™ through the American Academy of Nurse Practitioners (AANP). AANP will accept *AMA PRA Category 1 Credit(s)*™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Note for California Nurses: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC's provider number is CEP15510.



PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Faculty



Miguel Regueiro, MD (Moderator)

Chief, Digestive Disease Institute

Professor in the Department of Medicine

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Cleveland, OH

Miguel Regueiro, MD, is the Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio as well as Professor in the Department of Medicine of Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.

Dr. Regueiro's main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course of Crohn's disease and ulcerative colitis. He leads research on postoperative prevention of Crohn's disease as well as on developing new models of health care, including the first-of-its kind specialty medical home for IBD.

Dr. Regueiro reports the following financial relationships:

Advisory Board: AbbVie Inc; ALFASIGMA, S.p.A; Allergan, Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Labs; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; Target PharmaSolutions, Inc.; and UCB, Inc.

Consultant: AbbVie Inc; ALFASIGMA, S.p.A; Allergan, Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Labs; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; Target PharmaSolutions, Inc.; and UCB, Inc.

Grants: AbbVie Inc.; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Other financial or material support:

CME Companies: CME Outfitters; Cornerstones of Care; GI Health Foundation; HMP Global; iMedX; Medscape; MJH Life Sciences; MD Education; Remedy; and WebMD

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Faculty



Jessica R. Allegretti, MD, MPH, FACG, AGAF

*Medical Director, Infusion Services
Director, Crohn's and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA*

Jessica R. Allegretti, MD, MPH is an Associate Professor of Medicine at Harvard Medical School in the Division of Gastroenterology, Hepatology and Endoscopy, and is the Medical Director of the Crohn's and Colitis Center at Brigham and Women's Hospital, where she built and leads the Clinical Trials Program and Fecal Microbiota Transplant Program. Dr. Allegretti graduated from The Miller School of Medicine at the University of Miami in Miami, Florida, trained in internal medicine at Massachusetts's General Hospital in Boston, Massachusetts, and completed her gastroenterology fellowship training at Brigham and Women's Hospital before joining faculty there. She later went on to receive a Master of Public Health degree from the Harvard School of Public Health in Boston, Massachusetts.

Dr. Allegretti is a physician-scientist dedicated to discovering and developing innovative microbiome therapeutics and novel treatments for inflammatory bowel disease (IBD). Her research focus is on the mechanism recurrent *C.difficile* infection (CDI) and the intersection of CDI and IBD. She has authored more than 100 peer-reviewed publications. She has received funding from the National Institutes of Health (NIH), the American College of Gastroenterology and the Crohn's and Colitis Foundation. Dr. Allegretti has been featured on Home Box Office (HBO), British Broadcasting Corporation (BBC), Netflix, the New York Times and numerous other media outlets. In 2020, Dr. Allegretti received the Sherman Emerging Leader Prize for Excellence in Crohn's and Colitis (IBD).

Dr. Allegretti reports the following financial relationships:

Consultant: AbbVie Inc.; Adiso Therapeutics; Bristol Myers Squibb Company; Ferring Pharmaceuticals; Finch Therapeutics; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.; Roivant Sciences; and Seres Therapeutics

Research Support: Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc.

Speakers Bureau: Abbvie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Faculty



Angelina E. Collins, MSN, ANP-BC

*Board Certified Nurse Practitioner
Inflammatory Bowel Disease Center
UC San Diego Health
La Jolla, CA*

Angelina Collins, MSN, ANP-BC, is a board-certified adult nurse practitioner in the Inflammatory Bowel Disease Center at the University of California San Diego. She received her master's degree in nursing from the University of San Diego. Ms. Collins is passionate about providing comprehensive, patient-centered care for all stages of Crohn's disease and ulcerative colitis, from newly diagnosed patients to those with longstanding conditions and complications as well as patients in clinical trials. Ms. Collins has been a board member of the Greater San Diego and Desert Area chapter of the Crohn's and Colitis Foundation since 2015 and currently serves as its health care provider committee chairperson.

Ms. Collins reports the following financial relationships:

Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.

Consultant: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Lilly; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Faculty



Edward V. Loftus, Jr., MD

Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD

Division of Gastroenterology and Hepatology

Mayo Clinic College of Medicine and Science

Co-Director, Advanced Inflammatory Bowel Disease Fellowship

Mayo Graduate School of Medicine

Rochester, MN

Edward V. Loftus, Jr., MD, is a gastroenterologist with extensive experience as a lecturer and clinician researcher in the field of inflammatory bowel diseases. He is the Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically for IBD at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Loftus has published over 475 original articles, book chapters, and editorials and more than 700 abstracts. He was awarded the American Gastroenterologist Association's Distinguished Clinician Award and the Research Mentor Award in Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) in 2019. Dr. Loftus has been the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease and has served as the local PI on multiple clinical trials of investigational agents for IBD. He currently serves on the steering committees of several clinical development programs in IBD.

Dr. Loftus reports the following financial relationships:

Advisory Board: Lilly and Morphic Therapeutic, Inc.

Consultant: AbbVie Inc.; Alvotech; Amgen Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma Inc.; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celltrion, Inc.; Fresenius Kabi; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Gossamer Bio; Iterative Health; Janssen Pharmaceuticals, Inc.; Ono Pharma USA, Inc.; Protagonist Therapeutics Inc.; Sun. Pharma; Surrozen; Takeda Pharmaceuticals U.S.A.; TR1X Bio; and UCB, Inc.

Grants: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; Celgene Corporation/Receptos, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; Theravance Biopharma; and UCB, Inc.

Stock Shareholder (directly purchased): Exact Sciences Corporation

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Peer Reviewers

Rebecca Vargas-Jackson, MD—no disclosures to report.

Shirley Michelle Franks, MSN, APRN, FNP-BC—no disclosures to report.

CMEO Staff/Planners

Thomas Mitchell, MSW—no disclosures to report.

John Jones, PharmD—no disclosures to report.

Kasey Brandt, PharmD—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sharon Tordoff—no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visualizing the Future

Advances in IL-23-Targeted Therapies in the Treatment of IBD

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



Downloadable Resources

Downloadable resources will be available at cmeoutfitters.com/IL23resources.

Engage with Us

Follow us [@cmeoutfitters](https://twitter.com/cmeoutfitters) for announcements about upcoming CME opportunities, healthcare news, and more!

*Thank you for
joining us today!*

